Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis

Abstract Background & Aims: The peroxisome proliferator-activated receptor γ (PPARγ) has been proposed as a key inhibitor of colitis through attenuation of nuclear factor κB (NF-κB) activity. In inflammatory bowel disease, activators of NF-κB, including the bacterial receptor toll-like receptor (TLR)4, are elevated. We aimed to determine the role of bacteria and their signaling effects on PPARγ regulation during inflammatory bowel disease (IBD). Methods: TLR4-transfected Caco-2 cells, germ-free mice, and mice devoid of functional TLR4 ( Lps d /Lps d mice) were assessed for their expression of PPARγ in colonic tissues in the presence or absence of bacteria. This nuclear receptor expression and the polymorphisms of gene also were assessed in patients with Crohn's disease (CD) and ulcerative colitis (UC), 2 inflammatory bowel diseases resulting from an abnormal immune response to bacterial antigens. Results: TLR4-transfected Caco-2 cells showed that the TLR4 signaling pathway elevated PPARγ expression and a PPARγ-dependent reporter in an Iκκβ dependent fashion. Murine and human intestinal flora induced PPARγ expression in colonic epithelial cells of control mice. PPARγ expression was significantly higher in the colon of control compared with Lps d /Lps d mice. Although PPARγ levels appeared normal in patients with CD and controls, UC patients displayed a reduced expression of PPARγ confined to colonic epithelial cells, without any mutation in the PPARγ gene. Conclusions: These data showed that the commensal intestinal flora affects the expression of PPARγ and that PPARγ expression is considerably impaired in patients with UC.

[1]  M. Arditi,et al.  Bacterial Lipopolysaccharide Activates NF-κB through Toll-like Receptor 4 (TLR-4) in Cultured Human Dermal Endothelial Cells , 2000, The Journal of Biological Chemistry.

[2]  M. Neuberger,et al.  A second B cell-specific enhancer 3' of the immunoglobulin heavy-chain locus , 1990, Nature.

[3]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[4]  D. Podolsky,et al.  Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease , 2000, Infection and Immunity.

[5]  J. Auwerx,et al.  PPAR gamma: an essential role in metabolic control. , 2001, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[6]  Matthias Mann,et al.  IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation , 1997 .

[7]  S. Loitsch,et al.  PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. , 2000, Biochemical and biophysical research communications.

[8]  J. Auwerx,et al.  Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus , 2000, International Journal of Obesity.

[9]  F. Shanahan.  Crohn's disease , 2002, The Lancet.

[10]  P. Clifton,et al.  Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. , 2001, Physiological reviews.

[11]  D. Podolsky,et al.  Lipopolysaccharide Activates Distinct Signaling Pathways in Intestinal Epithelial Cell Lines Expressing Toll-Like Receptors1 , 2000, The Journal of Immunology.

[12]  E. de Rock,et al.  An easy method of layering blood over Ficoll-Paque gradients. , 1977, Journal of immunological methods.

[13]  J. Auwerx,et al.  Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. , 1999, Gastroenterology.

[14]  Jiandie D. Lin,et al.  Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. , 2001, Molecular cell.

[15]  M. Abreu,et al.  Decreased Expression of Toll-Like Receptor-4 and MD-2 Correlates with Intestinal Epithelial Cell Protection Against Dysregulated Proinflammatory Gene Expression in Response to Bacterial Lipopolysaccharide1 , 2001, The Journal of Immunology.

[16]  C. Datz,et al.  Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. , 1999, The Journal of endocrinology.

[17]  M. Neuberger,et al.  The half-life of immunoglobulin mRNA increases during B-cell differentiation: a possible role for targeting to membrane-bound polysomes. , 1988, Genes & development.

[18]  H. Blau,et al.  Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed , 1983, Molecular and cellular biology.

[19]  F. Forestier,et al.  A peptide derived from bovine beta-casein modulates functional properties of bone marrow-derived macrophages from germfree and human flora-associated mice. , 2001, The Journal of nutrition.

[20]  V. Sottile,et al.  Computed tomography in Crohn's disease. , 1982, The American journal of gastroenterology.

[21]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[22]  An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis , 2001 .

[23]  M. Hornef,et al.  Toll-like Receptor 4 Resides in the Golgi Apparatus and Colocalizes with Internalized Lipopolysaccharide in Intestinal Epithelial Cells , 2002, The Journal of experimental medicine.

[24]  A. Price.  Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'. , 1978, Journal of clinical pathology.

[25]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[26]  Y. Terauchi,et al.  Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury , 2001 .

[27]  Y. Lee,et al.  Effects of Peroxisome Proliferator-activated Receptor-γ (PPAR-γ) on the Expression of Inflammatory Cytokines and Apoptosis Induction in Rheumatoid Synovial Fibroblasts and Monocytes , 2001 .

[28]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[29]  P. Gionchetti,et al.  Bacteria as the cause of ulcerative colitis , 2001, Gut.

[30]  J. Gustafsson,et al.  Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. , 1996, Biochemical and biophysical research communications.

[31]  S. Deeb,et al.  The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[32]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[33]  F. T. ten Kate,et al.  Differential diagnosis of inflammatory bowel disease. A comparison of various diagnostic classifications. , 1991, Scandinavian journal of gastroenterology.

[34]  J. Auwerx,et al.  Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients , 1997, Diabetes.

[35]  P. Tak,et al.  NF-κB: a key role in inflammatory diseases , 2001 .

[36]  J. Auwerx,et al.  A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. , 1998, Human molecular genetics.

[37]  J. Reddy,et al.  Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. , 1998, The American journal of pathology.

[38]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[39]  Ehrhardt Ro.  New insights into the immunopathology of chronic inflammatory bowel disease. , 1996 .

[40]  Yasuo Suzuki,et al.  Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. , 2002, Biochemical and biophysical research communications.

[41]  J. Auwerx,et al.  Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) Heterodimer , 2001, The Journal of experimental medicine.

[42]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[43]  K. Karlinger,et al.  The epidemiology and the pathogenesis of inflammatory bowel disease. , 2000, European journal of radiology.

[44]  P. Desreumaux,et al.  Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. , 1997, Gastroenterology.

[45]  C. Glass,et al.  15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Toy,et al.  Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. , 1997, The Journal of clinical investigation.

[47]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.